MaxCyte stock surges 25% on raised 2026 revenue guidance

MaxCyte Inc (NASDAQ:MXCT) shares experienced a 25% surge following the cell-engineering company's announcement of raised full-year 2026 revenue guidance. The company reported a strong third-quarter performance, with core business revenue reaching approximately $8.1 million, marking a 26% year-over-year increase. MaxCyte also recorded Strategic Platform License Program-related revenue of over $1.0 million, including a $1.0 million milestone payment.

The company raised its full-year 2026 revenue guidance to around $34 million, surpassing the previous estimate of $31.45 million. This growth is attributed to accelerated instrument purchasing from a major customer and the expansion of late-stage clinical programs under its Strategic Platform License partnerships. The updated guidance indicates a 15% year-over-year growth in core business revenue for the second half of 2026.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.